N'-(2-羟基-5-甲氧基苯甲基)-4-二甲氨基苯甲酰肼及其氧钒(Ⅴ)配合物:合成、晶体结构和脲酶抑制活性

制备了一个苯甲酰腙化合物N'-(2-羟基-5-甲氧基苯甲基)-4-二甲氨基苯甲酰肼(H₂L)。利用H₂L、乙酰氧肟酸(HAHA)和VO(acac)₂在甲醇中反应得到了配合物[VOL(AHA)]。通过元素分析、红外和紫外光谱,以及单晶X-射线衍射对H₂L和其配合物进行了表征。苯甲酰腙配体作为二价阴离子,利用其酚羟基氧原子、亚胺基氮原子、以及烯醇氧原子与V原子进行配位。乙酰氧肟酸配体利用其羰基氧原子和去质子化的羟基氧原子进行配位。配合物中的V原子为八面体配位构型。测试了H₂L、HAHA和钒配合物的脲酶抑制活性。在浓度为100μmol·L^-1时,钒配合物对幽门螺旋杆菌脲酶的抑制率为63%,其IC₅₀值为45μmol·L^-1。还利用分子对接技术研究了配合物分子与脲酶的作用方式。     

丙二酰二腙衍生的二氧化二钼(Ⅵ)配合物的合成、表征和晶体结构

本文报道了二氧杂钼(Ⅵ)配合物[MoO₂(H₂L)(H₂O)]的合成、表征和分子结构。该配合物是由马来酰二腙配体双(2-羟基-1-萘醛)丙二酰二腙(H₄L)与双(乙酰丙酮)二氧钼(Ⅵ)在甲醇中以1∶1的物质的量之比反应得到的。通过各种光谱(如IR、MS和NMR)对该配合物进行了表征。通过单晶X射线晶体学确定了配合物的结构。该配合物属于单斜晶系P2₁/c空间群。金属中心具有扭曲的八面体配位环境,与H₂L^2-的1个甲亚胺氮原子、2个末端氧基团、H₂L^2-的2个氧原子和配位水分子的1个氧原子相连。     

丙二酰二腙衍生的二氧化二钼(Ⅵ)配合物的合成、表征和晶体结构

本文报道了二氧杂钼(Ⅵ)配合物[MoO₂(H₂L)(H₂O)]的合成、表征和分子结构。该配合物是由马来酰二腙配体双(2-羟基-1-萘醛)丙二酰二腙(H₄L)与双(乙酰丙酮)二氧钼(Ⅵ)在甲醇中以1∶1的物质的量之比反应得到的。通过各种光谱(如IR、MS和NMR)对该配合物进行了表征。通过单晶X射线晶体学确定了配合物的结构。该配合物属于单斜晶系P2₁/c空间群。金属中心具有扭曲的八面体配位环境,与H₂L^2-的1个甲亚胺氮原子、2个末端氧基团、H₂L^2-的2个氧原子和配位水分子的1个氧原子相连。     

含乙酰氧肟酸配体的席夫碱钒配合物的合成、结构及其抑制幽门螺旋杆菌脲酶研究

本文合成了2个新的含乙酰氧肟酸配体的席夫碱钒配合物,[V^ⅢL¹(HAHA)](1)和[V^ⅤOL²(AHA)](2),其中L¹为N,N’-二(5-甲基水杨基)乙烷-1,2-二胺的二价阴离子,L²为2-{[2-(2-羟乙基氨基)乙亚胺基]甲基}-6-甲基苯酚的一价阴离子,HAHA和AHA分别为乙酰氧肟酸的一价和二价阴离子,通过物理-化学方法以及单晶X-射线衍射表征了它们的结构。在每个化合物中,V原子都采取八面体配位构型。本文还研究了配合物的热稳定性以及其对幽门螺旋杆菌脲酶的抑制活性。在浓度为100μmol·L^-1时,配合物1和2对脲酶的抑制率分别为37.2%和81.5%,其中配合物2的IC₅₀值为21.5μmol·L^-1。分子对接研究表明配合物2与脲酶活性中心存在有效的作用力。     

二个含水杨酰腙配体的钒配合物的合成与晶体结构研究

2种水杨酰腙配体H₂L¹(H₂L¹=邻羟基苯乙酮缩水杨酰腙)和H₂L²(H₂L²=水杨醛缩水杨酰腙)分别与VO(acac)₂反应, 合成了2个钒配合物[VOL¹(C₂H₅O)]₂ (1)和[VOL²(i-C₃H₇O)](2), 利用元素分析、红外光谱、紫外光谱和单晶衍射等手段进行表征。配合物1是由酚氧原子桥联2个金属中心形成的具有晶体学中心对称性的双核钒(Ⅴ)配合物结构, 每个V(Ⅴ)原子具有扭曲的八面体配位构型。配合物2为单核结构, 每个V(Ⅴ)原子具有扭曲的四角锥配位构型, 相邻的配合物分子通过分子间氢键作用形成一维超分子链状结构。采用循环伏安法研究了化合物2的电化学性质。     

一个基于N'-(3-溴-5-氯-2-羟基苯亚甲基)-3-羟基-4-甲氧基苯甲酰肼的甲基麦芽酚配位的氧钒(Ⅴ)配合物:合成、晶体结构及其胰岛素增强活性

制备了1个芳酰腙化合物:N'-(3-溴-5-氯-2-羟基苯亚甲基)-3-羟基-4-甲氧基苯甲酰肼(H₂L),并利用元素分析、红外、紫外、高分辨质谱、核磁共振氢谱和碳谱对其进行了表征。利用H₂L与甲基麦芽酚和VO(acac)₂在甲醇中反应得到了1个甲基麦芽酚配位的氧钒(Ⅴ)配合物[VO(mat)L]·MeOH。通过元素分析、红外和紫外光谱对其进行了表征,同时还研究了配合物的热稳定性。通过单晶X射线衍射进一步确认了H₂L和配合物的结构。通过对C2C12肌细胞的胰岛素模拟实验,表明该配合物能显著促进细胞对葡萄糖的利用,其细胞毒性仅为0.07 g·L^-1。     

基于4-氟-N'-(3-乙氧基-2-羟基苯亚甲基)苯甲酰肼的甲基麦芽酚和乙基麦芽酚配位的氧钒(Ⅴ)配合物的合成、晶体结构及其类胰岛素活性

制备了一个芳酰腙化合物4-氟-N''-（3-乙氧基-2-羟基苯亚甲基）苯甲酰肼（H₂L）。利用H₂L和VO（acac）₂分别与甲基麦芽酚（mat）和乙基麦芽酚（Emat）在甲醇中反应,得到了2个配合物[VO（L）（mat）]（1）和[VO（L）（Emat）]（2）。通过元素分析、红外光谱、紫外可见光谱和核磁共振氢谱表征了这些化合物的结构。通过单晶X射线衍射进一步确定了化合物的结构。芳酰腙配体以二价阴离子的方式通过酚羟基氧、亚胺基氮和烯醇氧原子与钒原子进行配位。在每个配合物中,钒都采取八面体配位构型。将配合物通过灌胃对正常的大鼠和四氧嘧啶糖尿病大鼠给药2周时间,结果表明这两个配合物在剂量为10.0和20.0 mgV·kg^-1时可以显著降低四氧嘧啶糖尿病大鼠的血糖值,而对于正常大鼠的血糖值却没有改变。     

基于4-氟-N'-（3-乙氧基-2-羟基苯亚甲基）苯甲酰肼的甲基麦芽酚和乙基麦芽酚配位的氧钒（Ⅴ）配合物的合成、晶体结构及其类胰岛素活性

制备了一个芳酰腙化合物4-氟-N''-（3-乙氧基-2-羟基苯亚甲基）苯甲酰肼（H₂L）。利用H₂L和VO（acac）₂分别与甲基麦芽酚（mat）和乙基麦芽酚（Emat）在甲醇中反应,得到了2个配合物[VO（L）（mat）]（1）和[VO（L）（Emat）]（2）。通过元素分析、红外光谱、紫外可见光谱和核磁共振氢谱表征了这些化合物的结构。通过单晶X射线衍射进一步确定了化合物的结构。芳酰腙配体以二价阴离子的方式通过酚羟基氧、亚胺基氮和烯醇氧原子与钒原子进行配位。在每个配合物中,钒都采取八面体配位构型。将配合物通过灌胃对正常的大鼠和四氧嘧啶糖尿病大鼠给药2周时间,结果表明这两个配合物在剂量为10.0和20.0 mgV·kg^-1时可以显著降低四氧嘧啶糖尿病大鼠的血糖值,而对于正常大鼠的血糖值却没有改变。     

2-羟基萘甲醛苯甲酰腙作配体的钼和钒两个化合物的合成和晶体结构

2-羟基萘甲醛苯甲酰腙(H₂L)由2-羟基萘甲醛和苯甲酰肼在乙醇溶液中制得。利用H₂L分别合成了钼和钒的配合物，[MoO₂(EtOH)L](1) 和 [VO(OMe)L(MeOH)](2)，并测定了它们的晶体结构。配合物1和2是类似的结构单元，钼和钒都采取扭曲的八面体配位构型。     

含取代芳酰腙和单齿N-杂环分子铜(II)配合物的合成、结构及荧光性质

合成了1个含有取代芳酰腙和单齿N-杂环分子的三元铜配合物[Cu(L)(ampy)](H₂L=5-溴水杨醛苯甲酰腙，ampy=2-氨基吡啶)，并通过IR、UV、荧光光谱和循环伏安进行了性质研究。[Cu(L)(ampy)]的晶体结构分析表明，中心金属通过酰腙配体的酚基氧原子、亚胺基氮原子、去质子酰胺氧原子以及中性杂环分子的氮原子形成平面四方形的N₂O₂配位环境。配合物通过N-H…O和N-H…N氢键作用形成一维链状结构。     

The total syntheses of (±)-α- and β-dihydro-cleavamines, (±)-16-methoxycarbonyldihydrocleavamine, (±)-coronaridine, (±)-dihydrocatharanthine, (±)-ibogamine, (±)-epi-ibogamine and (±)-catharanthine2

The total syntheses of (±)α- and β-dihydrocleavamines, (±)-16-methoxycarbonyldihydro-cleavamine, (±)-coronaridine, (±)-dihydrocatharanthine, (±)-ibogamine, (±)-epi-ibogamine and (±)-catharanthine are described.     

Bis(dimethylmetall(III)glyoximato)metallate(II) (metall(III) = Al,Ga, In,metall(II) = Ni,Pd, Pt,Cu)

When the trimethyl derivatives of aluminium, gallium and indium react with glyoximato metallates, (R₂C₂N₂(O)OH)₂Met^II (R = H, CH₃; Met^II = Ni, Pd, Pt, Cu), in a $\text{2}\text{1}$ molar ratio, 2 mol of methane are evolved and monomeric bis(dimethylmetal(III)glyoximato)metallates(II) (metal(III) = Al, Ga, In) are formed in high yields. The vibrational and NMR spectra of the new complexes were measured and were partly resolved. The X-ray structure determinations of two of these compounds show non-planar structures of approximate C_2h and C₂ symmetry, respectively, with weak metal(III)?metal(II) π-interactions.     

Monomeric Bis(eta(2)-alkyne)copper(I) and -silver(I) Halides, Pseudohalides, and Arenethiolates

The synthesis and characterization of the complexes [(eta(5)-C(5)H(4)SiMe(3))(2)Ti(C&tbd1;CSiMe(3))(2)]MX (M = Cu, X = OTf (2), SC(6)H(5) (4), SC(6)H(4)NMe(2)-2 (5), SC(6)H(4)CH(2)NMe(2)-2 (6), S-1-C(10)H(6)NMe(2)-8 (7), Cl (8), (N&tbd1;CMe)PF(6) (9); M = Ag, X = OTf (3)) are described. These complexes contain monomeric MX entities, which are eta(2)-bonded by both alkyne functionalities of the organometallic bis(alkyne) ligand [(eta(5)-C(5)H(4)SiMe(3))(2)Ti(C&tbd1;CSiMe(3))(2)] (1). The reactions of 2 with the Lewis bases N&tbd1;CPh and N&tbd1;CC(H)=C(H)C&tbd1;N afford the cationic complexes {[(eta(5)-C(5)H(4)SiMe(3))(2)Ti(C&tbd1;CSiMe(3))(2)]Cu(N&tbd1;CPh)}OTf (10) and {[(eta(5)-C(5)H(4)SiMe(3))(2)Ti(C&tbd1;CSiMe(3))(2)]Cu}(2)(N&tbd1;CC(H)=C(H)C&tbd1;N)(OTf)(2) (11), respectively. The X-ray structures of 2, 3, and 6 have been determined. Crystals of 2 are monoclinic, space group P2(1)/c, with a = 12.8547(7) ?, b = 21.340(2) ?, c = 18.279(1) ?, beta = 133.623(5) degrees, V= 3629.7(5) ?(3), Z = 4, and final R = 0.047 for 5531 reflections with I >/= 2.5sigma(I) and 400 variables. The silver triflate complex 3 is isostructural, but not isomorphous, with the corresponding copper complex 2, and crystals of 3 are monoclinic, space group P2(1)/c, with a = 13.384(3) ?, b = 24.55(1) ?, c = 13.506(3) ?, beta = 119.21(2) degrees, V = 3873(2) ?(3), Z = 4, and final R = 0.038 for 3578 reflections with F >/= 4sigma(F) and 403 variables. Crystals of the copper arenethiolate complex 6 are triclinic, space group P&onemacr;, with a = 11.277(3) ?, b = 12.991(6) ?, c = 15.390(6) ?, alpha = 65.17(4) degrees, beta = 78.91(3) degrees, gamma = 84.78(3) degrees, V = 2008(2) ?(3), Z = 2, and final R = 0.079 for 6022 reflections and 388 variables. Complexes 2-11 all contain a monomeric bis(eta(2)-alkyne)M(eta(1)-X) unit (M = Cu, Ag) in which the group 11 metal atom is trigonally coordinated by the chelating bis(eta(2)-alkyne) entity Ti(C&tbd1;CSiMe(3))(2) and an eta(1)-bonded monoanionic ligand X. The copper arenethiolate complexes 4-7 are fluxional in solution.     

N,N'-ethylenebis(pyridoxylideneiminato) and N,N'-ethylenebis(pyridoxylaminato): synthesis, characterization, potentiometric, spectroscopic, and DFT studies of their vanadium(IV) and vanadium(V) complexes

The Schiff base N,N'-ethylenebis(pyridoxylideneiminato) (H(2)pyr(2)en, 1) was synthesized by reaction of pyridoxal with ethylenediamine; reduction of H(2)pyr(2)en with NaBH(4) yielded the reduced Schiff base N,N'-ethylenebis(pyridoxylaminato) (H(2)Rpyr(2)en, 2); their crystal structures were determined by X-ray diffraction. The totally protonated forms of 1 and 2 correspond to H(6)L(4+), and all protonation constants were determined by pH-potentiometric and (1)H NMR titrations. Several vanadium(IV) and vanadium(V) complexes of these and other related ligands were prepared and characterized in solution and in the solid state. The X-ray crystal structure of [V(V)O(2)(HRpyr(2)en)] shows the metal in a distorted octahedral geometry, with the ligand coordinated through the N-amine and O-phenolato moieties, with one of the pyridine-N atoms protonated. Crystals of [(V(V)O(2))(2)(pyren)(2)].2 H(2)O were obtained from solutions containing H(2)pyr(2)en and oxovanadium(IV), where Hpyren is the "half" Schiff base of pyridoxal and ethylenediamine. The complexation of V(IV)O(2+) and V(V)O(2) (+) with H(2)pyr(2)en, H(2)Rpyr(2)en and pyridoxamine in aqueous solution were studied by pH-potentiometry, UV/Vis absorption spectrophotometry, as well as by EPR spectroscopy for the V(IV)O systems and (1)H and (51)V NMR spectroscopy for the V(V)O(2) systems. Very significant differences in the metal-binding abilities of the ligands were found. Both 1 and 2 act as tetradentate ligands. H(2)Rpyr(2)en is stable to hydrolysis and several isomers form in solution, namely cis-trans type complexes with V(IV)O, and alpha-cis- and beta-cis-type complexes with V(V)O(2). The pyridinium-N atoms of the pyridoxal rings do not take part in the coordination but are involved in acid-base reactions that affect the number, type, and relative amount of the isomers of the V(IV)O-H(2)Rpyr(2)en and V(V)O(2)-H(2)Rpyr(2)en complexes present in solution. DFT calculations were carried out and support the formation and identification of the isomers detected by EPR or NMR spectroscopy, and the strong equatorial and axial binding of the O-phenolato in V(IV)O and V(V)O(2) complexes. Moreover, the DFT calculations done for the [V(IV)O(H(2)Rpyr(2)en)] system indicate that for almost all complexes the presence of a sixth equatorial or axial H(2)O ligand leads to much more stable compounds.